HT-1 Treatment
Hereditary Tyrosinemia Type 1 (HT-1)
CommercialActive
Key Facts
Indication
Hereditary Tyrosinemia Type 1 (HT-1)
Phase
Commercial
Status
Active
Company
About Cycle Pharmaceuticals
Cycle Pharmaceuticals is a patient-centric, commercial-stage biopharma company specializing in rare and underserved diseases. It leverages a hybrid model of developing/acquiring treatments and wrapping them in its proprietary Cycle Vita™ patient support ecosystem, which provides clinical, dietary, and access services. The company is actively expanding its U.S. footprint through new product launches and strategic acquisitions, as evidenced by its 2026 tender offer for Applied Therapeutics, positioning it for growth in the high-need, high-value rare disease market.
View full company profile